繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 肿瘤 >> 白血病 >> 药品推荐 >> Atriance(nelarabine solution for infusion)

Atriance(nelarabine solution for infusion)

2015-09-27 09:39:08  作者:新特药房  来源:互联网  浏览次数:0  文字大小:【】【】【
简介: 英文药名:Atriance(nelarabine Injection) 中文药名:奈拉滨注射剂 生产厂家:葛兰素史克药品介绍奈拉滨(Nekarabine,美国上市的商品名:Arranon,欧洲上市的商品名:Atriance 公司:葛兰素史克)是 ...

英文药名:Atriance(nelarabine Injection)

中文药名:奈拉滨注射剂

生产厂家:葛兰素史克
药品介绍
奈拉滨(Nekarabine,美国上市的商品名:Arranon,欧洲上市的商品名:Atriance 公司:葛兰素史克)是一种嘌呤类似物抗代谢药,其批准上市日期为2005年10月28日。
适应症
奈拉滨主要用于曾经接受过至少两种化疗方案治疗但仍无应答,或病情出现复发的急性T细胞型淋巴母细胞白血病及T细胞型淋巴母细胞淋巴瘤患者。
药理及药代动力学
奈拉滨是脱氧鸟苷类似物9-b-D-阿糖呋喃糖鸟嘌呤(ara-G)的前体药物。奈拉滨在腺苷脱氨酶(ADA)的作用下脱去甲基转变为ara-G,随后,又在脱氧鸟苷激酶和脱氧胞苷激酶的作用下,经单磷酸化作用途径转变为具有活性的ara-G三磷酸盐(ara-GTP)。ara-GTP可在白血病原始细胞(keukemic bkast cekk)中逐渐积聚,并与DNA相结合,从而起到抑制DNA合成,促进白血病细胞死亡的作用。此外,奈拉滨的抗癌机制可能还与其细胞毒性和全身毒性作用有关。
复发性白血病或淋巴瘤患者的药代动力学研究发现,奈拉滨和ara-G在血浆中的消除迅速,在给予1500mg/m2剂量的奈拉滨后,两者半衰期分别为30分钟和3小时。研究还发现,ara-G通常在奈拉滨给药完毕时达到峰浓度,而且其峰浓度数值通常也大于奈拉滨的峰浓度,表明奈拉滨可在体内迅速、完全地转化为ara-G。奈拉滨和ara-G部分经肾脏消除,28名成年患者在给予奈拉滨后24小时测得的奈拉滨和ara-G的平均肾排泄率分别为6.6±4.7%和27±15%。
注意事项
奈拉滨所致的神经毒性属于剂量限制性毒性反应。患者在用药期间应密切留意是否出现意识模糊、嗜睡、惊厥、共济失调、感觉异常和感觉减退等症状。曾经接受过鞘内化疗或颅脊放疗的患者应用奈拉滨后出现神经毒性反应的风险将增大。
奈拉滨还有可能引起白细胞减少症、血小板减少症、贫血和中性粒细胞减少症(包括发热性中性粒细胞减少症),因此应用奈拉滨的患者应常规进行全血细胞计数(包括血小板计数)。
根据标准治疗方案,正在应用奈拉滨的肿瘤溶解综合征患者并发高尿酸血症时,可通过静脉水合方式加以缓解;存在高尿酸血症风险的患者还可考虑服用别嘌醇进行治疗。应用奈拉滨的免疫缺陷患者应避免注射活疫苗。
药物相互作用
迄今尚未见有关奈拉滨和ara-G药物相互作用的报道。体内实验发现,奈拉滨和ara-G不会明显抑制人细胞色素P450同功酶1A2、2A6、2B6、2C8、2C9、2C19、2D6或3A4的活性。
不良反应
儿童患者应用奈拉滨后最常见的是血液系统不良事件(如贫血、白细胞减少、中性粒细胞减少和血小板减少)。在非血液系统不良事件中,最常见的是头痛、转氨酶水平升高、血钾水平降低、血白蛋白水平降低、血胆红素水平升高和呕吐。
成年患者应用奈拉滨后最常见的不良事件为疲劳、胃肠道不适(如恶心、腹泻、呕吐和便秘)、血液系统不良事件(如贫血、中性粒细胞减少和血小板减少)、呼吸系统不良事件(咳嗽和呼吸困难)、神经系统不良事件(嗜睡和头晕)以及发热。
剂量及用药
奈拉滨注射剂为澄清、无色、无菌溶液,其规格为50mk∶250mg,储存在聚氯乙烯(PVC)输液袋或玻璃瓶中。奈拉滨注射剂经静脉给药,无需再进行稀释,成人患者每次静脉输注时间为2小时,儿童患者则为1小时。给予奈拉滨注射剂前,护士或药师应目测检查制剂产品中是否含有微粒物质或是否发生颜色改变。
奈拉滨的成人推荐剂量为1500mg/m2,分别在治疗开始第1天、第3天和第5天给药,每21天重复给药一次。奈拉滨的儿童推荐剂量为650 mg/m2,在治疗开始第1至第5天连续5天给药,每21天重复给药一次。成人及儿童患者用奈拉滨治疗的推荐疗程尚未建立。在临床试验中,受试者通常一直用药,直到出现以下情况:患者病情出现进展,患者不能耐受毒性反应,患者有望接受骨髓移植或者患者通过药物治疗不能再获得更多的好处。
用药提示
由于患者应用奈拉滨后可能出现嗜睡,因此患者在用药期间应避免操作具有危险性的机械,包括驾驶机动车。当患者出现新的周围神经病症状或原有症状加重时,应告知医师加以处理,这些体征和症状包括:手指、手部、脚趾和足部出现麻刺或麻木感;精细运动协调功能(如扣钮扣)出现障碍;走路不稳;从位置较低的椅子上起立时感到无力;上楼梯时感到无力;以及在不平坦地面上走路时容易跌倒等等。
应告知患者应用奈拉滨后可能会出现癫痫发作。因此,如果出现癫痫发作,患者应立即通知医生进行处理。此外,患者在用药过程中若出现发烧或感染症状,也应立即告知医生。
包装规格
250mg*6瓶/盒
生产商:德国GlaxoSmithKline
Atriance 5 mg/ml solution for infusion
1. Name of the medicinal product
Atriance® 5 mg/ml solution for infusion
2. Qualitative and quantitative composition
Each ml of solution contains 5 mg of nelarabine.
Each vial contains 250 mg of nelarabine.
Excipient with known effect: each ml of solution contains 1.725 mg (75 micromols) of sodium.
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Solution for infusion.
Clear, colourless solution.
4. Clinical particulars
4.1 Therapeutic indications
Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
Due to the small patient populations in these disease settings, the information to support these indications is based on limited data.
4.2 Posology and method of administration
Nelarabine is for intravenous use only and must only be administered under the supervision of a physician experienced in the use of cytotoxic agents.
Posology
Patients receiving nelarabine are recommended to receive intravenous hydration according to standard medical practice for the management of hyperuricaemia in patients at risk for tumour lysis syndrome. For patients at risk of hyperuricaemia, the use of allopurinol should be considered (see section 4.4).
Complete blood counts including platelets must be monitored regularly (see sections 4.4 and 4.8).
Adults and adolescents (aged 16 years and older)
The recommended dose of nelarabine for adults is 1,500 mg/m2 administered intravenously over two hours on days 1, 3 and 5 and repeated every 21 days.
Paediatric population
Children and adolescents (aged 21 years and younger)
The recommended dose of nelarabine for children and adolescents is 650 mg/m2 administered intravenously over one hour daily for 5 consecutive days, repeated every 21 days.
In clinical studies, the 650 mg/m2 and 1,500 mg/m2 dose have both been used in patients in the age range 16 to 21 years. Efficacy and safety were similar for both regimens. The prescribing physician should consider which regimen is appropriate when treating patients in this age range.
Limited clinical pharmacology data are available for patients below the age of 4 years (see section 5.2).
Dose modification
Nelarabine must be discontinued at the first sign of neurological events of National Cancer Institute Common Terminology Criteria Adverse Event (NCI CTCAE) grade 2 or greater. Delaying subsequent dosing is an option for other toxicities, including haematological toxicity.
Elderly
Insufficient numbers of patients aged 65 years of age and older have been treated with nelarabine to determine whether they respond differently than younger patients (see sections 4.4 and 5.2).
Renal Impairment
Nelarabine has not been studied in individuals with renal impairment. Nelarabine and 9-β-D-arabinofuranosylguanine (ara-G) are partially renally excreted (see section 5.2). There are insufficient data to support a dose adjustment recommendation for patients with a renal clearance of creatinine Clcr less than 50 ml/min. Patients with renal impairment must be closely monitored for toxicities when treated with nelarabine.
Hepatic Impairment
Nelarabine has not been studied in patients with hepatic impairment. These patients should be treated with caution.
Method of administration
Nelarabine must not be diluted prior to administration. The appropriate dose of nelarabine must be transferred into polyvinylchloride (PVC) or ethyl vinyl acetate (EVA) infusion bags or glass containers and administered intravenously as a two-hour infusion in adult patients and as a one-hour infusion in paediatric patients.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
4.4 Special warnings and precautions for use
NEUROLOGICAL ADVERSE REACTIONS
Severe neurological reactions have been reported with the use of nelarabine. These reactions have included altered mental states including severe somnolence, central nervous system effects including convulsions, and peripheral neuropathy ranging from numbness and paresthesias to motor weakness and paralysis. There have also been reports of reactions associated with demyelination, and ascending peripheral neuropathies similar in appearance to Guillain-Barré Syndrome.

Full recovery from these reactions has not always occurred with cessation of nelarabine. Therefore, close monitoring for neurological reactions is strongly recommended, and nelarabine must be discontinued at the first sign of neurological reactions of NCI CTCAE Grade 2 or greater.
Neurotoxicity is the dose-limiting toxicity of nelarabine. It is advised that patients undergoing therapy with nelarabine be closely observed for signs and symptoms of neurological toxicity.
Common signs and symptoms of nelarabine-related neurotoxicity include somnolence, confusion, convulsions, ataxia, paraesthesias, and hypoesthesia. Severe neurological toxicity can manifest as coma, status epilepticus, demyelination, or ascending neuropathy similar in appearance to Guillain-Barré syndrome (see section 4.8).
Patients treated previously or concurrently with intrathecal chemotherapy or previously with craniospinal irradiation are potentially at increased risk for neurological adverse events (see section 4.2 - dose modification) and therefore concomitant intrathecal therapy and/or craniospinal irradiation is not recommended.
Immunisation using a live organism vaccine has the potential to cause infection in immunocompromised hosts. Therefore, immunisations with live organism vaccines are not recommended.
Leukopenia, thrombocytopenia, anaemia, and neutropenia, (including febrile neutropenia) have been associated with nelarabine therapy. Complete blood counts including platelets must be monitored regularly (see sections 4.2 and 4.8).
Patients receiving nelarabine are recommended to receive intravenous hydration according to standard medical practice for the management of hyperuricaemia in patients at risk of tumour lysis syndrome. For patients at risk of hyperuricaemia, the use of allopurinol should be considered.
Elderly
Clinical studies of nelarabine did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In an exploratory analysis, increasing age, especially aged 65 years and older, appeared to be associated with increased rates of neurological adverse events.
Carcinogenicity and mutagenicity
Carcinogenicity testing of nelarabine has not been performed. Nelarabine however, is known to be genotoxic to mammalian cells (see section 5.3).
Sodium warning
This medicinal product contains 1.725 mg/ml (75 micromols) of sodium. To be taken into consideration by patients on a controlled sodium diet.
4.5 Interaction with other medicinal products and other forms of interaction
Nelarabine and ara-G did not significantly inhibit the activities of the major hepatic cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 in vitro.
Concomitant administration of nelarabine in combination with adenosine deaminase inhibitors, such as pentostatin is not recommended. Concomitant administration may reduce the efficacy of nelarabine and/or change the adverse event profile of either active substance.
4.6 Fertility, pregnancy and lactation
Contraception in males and females
Both sexually active men and women should use effective methods of contraception during treatment and for at least three months following cessation of treatment.
Pregnancy
There are no adequate data from the use of nelarabine in pregnant women.
Studies in animals have shown reproductive toxicity including malformations (see section 5.3). The potential risk in humans is unknown, however, exposure during pregnancy will likely lead to anomalies and malformations of the foetus.
Nelarabine should not be used during pregnancy unless clearly necessary. If a patient becomes pregnant during treatment with nelarabine, they should be informed of the possible risk to the foetus.
Breastfeeding
It is unknown whether nelarabine or its metabolites are excreted in human breast milk. The excretion of nelarabine in milk has not been studied in animals. However, because of the potential for serious adverse reactions in infants, breastfeeding should be discontinued.
Fertility
The effect of nelarabine on fertility in humans is unknown. Based on the pharmacological action of the compound, undesirable effects on fertility are possible. Family planning should be discussed with patients as appropriate.
4.7 Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed.
Patients treated with nelarabine are potentially at risk of suffering from somnolence during and for several days after treatment. Patients must be cautioned that somnolence can affect performance of skilled tasks, such as driving.
4.8 Undesirable effects
Summary of the safety profile
The safety profile from pivotal clinical trials at the recommended doses of nelarabine in adults (1,500 mg/m2) and children (650 mg/m2) is based on data from 103 adults and 84 paediatric patients respectively. The most frequently occurring adverse events were fatigue; gastrointestinal disorders; haematological disorders; respiratory disorders; nervous system disorders; and pyrexia. Neurotoxicity is the dose limiting toxicity associated with nelarabine therapy (see section 4.4).
Tabulated list of adverse reactions
The following convention has been utilised for the classification of frequency: Very common (≥1/10), Common (≥ 1/100 to < 1/10), Uncommon (≥ 1/1,000 to < 1/100), Rare (≥ 1/10,000 to < 1/1,000) and Very rare (< 1/10,000), not known (cannot be estimated from the available data)

Adverse events(s)

Adults (1,500 mg/m2)

N=103 (%)

Children (650 mg/m2)

N=84 (%)

Infections and infestations

Infection (including but not limited to; sepsis, bacteraemia, pneumonia, fungal infection)

Very common: 40 (39)

Very common: 13 (15)

Neoplasms benign and malignant (including cysts and polyps)

Tumour lysis syndrome (see also Data from compassionate use programme and non-pivotal studies)

Common: 1 (1)

N/A

Blood and lymphatic system disorders

Febrile neutropenia

Very common: 12 (12)

Common: 1(1)

Neutropenia

Very common: 83(81)

Very common: 79 (94)

Leukopenia

Common: 3 (3)

Very common: 32 (38)

Thrombocytopenia

Very common: 89 (86)

Very common: 74 (88)

Anaemia

Very common: 102 (99)

Very common: 80 (95)

Metabolism and nutrition disorders

Hypoglycaemia

N/A

Common: 5 (6)

Hypocalcaemia

Common: 3 (3)

Common: 7 (8)

Hypomagnesaemia

Common: 4 (4)

Common: 5 (6)

Hypokalaemia

Common: 4 (4)

Very common: 9 (11)

Anorexia

Common: 9 (9)

N/A

Psychiatric disorders

Confusional state

Common: 8 (8)

Common: 2 (2)

Nervous system disorders

Seizures (including convulsions, grand mal convulsions, status epilepticus)

Common: 1 (1)

Common: 5 (6)

Amnesia

Common: 3 (3)

N/A

Somnolence

Very common: 24 (23)

Common: 6 (7)

Peripheral neurological disorders (sensory and motor)

Very common: 22 (21)

Very common: 10 (12)

Hypoesthesia

Very common: 18 (17)

Common: 5 (6)

Paresthesia

Very common: 15 (15)

Common: 3 (4)

Ataxia

Common: 9 (9)

Common: 2 (2)

Balance disorder

Common: 2 (2)

N/A

Tremor

Common: 5 (5)

Common: 3 (4)

Dizziness

Very common: 22 (21)

N/A

Headache

Very common: 15 (15)

Very common: 14 (17)

Dysgeusia

Common: 3 (3)

N/A

Eye disorders

Blurred vision

Common: 4(4)

N/A

Vascular disorders

Hypotension

Common: 8 (8)

N/A

Respiratory, thoracic, and mediastinal disorders

Pleural effusion

Common: 10 (10)

N/A

Wheezing

Common: 5 (5)

N/A

Dyspnoea

Very common: 21 (20)

N/A

Cough

Very common: 26 (25)

N/A

Gastrointestinal disorders

Diarrhoea

Very common: 23 (22)

Common: 2 (2)

Stomatitis

Common: 8 (8)

Common: 1 (1)

Vomiting

Very common: 23 (22)

Common: 8 (10)

Abdominal pain

Common: 9(9)

N/A

Constipation

Very common: 22 (21)

Common: 1 (1)

Nausea

Very common: 42 (41)

Common: 2 (2)

Hepatobiliary disorders

Hyperbilirubinaemia

Common: 3 (3)

Common: 8 (10)

Transaminases increased

N/A

Very common: 10(12)

Aspartate aminotransferase increased

Common: 6 (6)

N/A

Musculoskeletal and connective tissue disorders

Muscle weakness

Common: 8 (8)

N/A

Myalgia

Very common: 13 (13)

N/A

Arthralgia

Common: 9 (9)

Common: 1 (1)

Back pain

Common: 8 (8)

N/A

Pain in extremity

Common: 7 (7)

Common: 2 (2)

Rhabdomyolysis, blood creatine phosphokinase increased (see Post – Marketing Data)

Rare: N/A

Rare: N/A

Renal and urinary disorders

Blood creatinine increased

Common: 2 (2)

Common: 5 (6)

General disorders and administrative site conditions

Oedema

Very common: 11 (11)

N/A

Gait abnormal

Common: 6 (6)

N/A

Oedema peripheral

Very common: 15 (15)

N/A

Pyrexia

Very common: 24 (23)

Common: 2 (2)

Pain

Very common: 11 (11)

N/A

Fatigue

Very common: 51 (50)

Common: 1 (1)

Asthenia

Very common: 18 (17)

Common: 5 (6)

There was a single additional report of biopsy confirmed progressive multifocal leukoencephalopathy in the adult population.
There have been reports of sometimes fatal opportunistic infections in patients receiving nelarabine therapy.
Nervous System disorders
There have been reports of events associated with demyelination and ascending peripheral neuropathies similar in appearance to Guillain-Barré syndrome.
One subject in the paediatric group had a fatal neurological event of status epilepticus.
Data from NCI studies/compassionate use programme and phase I studies
In addition to the adverse reactions seen in the pivotal clinical trials, there are also data from 875 patients from NCI studies/compassionate use programme (694 patients) and Phase I (181 patients) studies of nelarabine. The following additional adverse reactions were seen:
Neoplasms benign and malignant (including cysts and polyps)
Tumour lysis syndrome – 7 cases (see sections 4.2 and 4.4)
Post – Marketing Data
The following adverse reactions have been identified during post-approval use of nelarabine. This includes spontaneous case reports as well as serious adverse events from ongoing studies.
Musculoskeletal and connective tissue disorders
Rare Rhabdomyolysis, blood creatine phosphokinase increased
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9 Overdose
No case of overdose has been reported.
Nelarabine has been administered in clinical trials up to a dose of 75 mg/kg (approximately 2,250 mg/m2) daily for 5 days to a paediatric patient, up to a dose of 60 mg/kg (approximately 2,400 mg/m2) daily for 5 days to 5 adult patients and up to 2,900 mg/m2 in a further 2 adults on days 1, 3 and 5.
Symptoms and signs
It is likely that nelarabine overdose would result in severe neurotoxicity (possibly including paralysis, coma), myelosuppression and potentially death. At a dose of 2200 mg/m2 given on days 1, 3 and 5 every 21 days, 2 patients developed a significant grade 3 ascending sensory neuropathy. MRI evaluations of the 2 patients demonstrated findings consistent with a demyelinating process in the cervical spine.
Treatment
There is no known antidote for nelarabine overdose. Supportive care consistent with good clinical practice should be provided.
5. Pharmacological properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antineoplastic agents, antimetabolites, purine analogues, ATC code: L01B B 07
Nelarabine is a pro-drug of the deoxyguanosine analogue ara-G. Nelarabine is rapidly demethylated by adenosine deaminase (ADA) to ara-G and then phosphorylated intracellularly by deoxyguanosine kinase and deoxycytidine kinase to its 5'-monophosphate metabolite. The monophosphate metabolite is subsequently converted to the active 5'-triphosphate form, ara-GTP. Accumulation of ara-GTP in leukaemic blasts allows for preferential incorporation of ara-GTP into deoxyribonucleic acid (DNA) leading to inhibition of DNA synthesis. This results in cell death. Other mechanisms may contribute to the cytotoxic effects of nelarabine. In vitro, T-cells are more sensitive than B-cells to the cytotoxic effects of nelarabine.
Clinical studies
Adult studies
In an open-label study carried out by the Cancer and Leukaemia Group B and the Southwest Oncology Group, the safety and efficacy of nelarabine were evaluated in 39 adults with T-cell acute lymphoblastic leukaemia (T-ALL) or lymphoblastic lymphoma (T-LBL). Twenty–eight of the 39 adults had relapsed or were refractory to at least two prior induction regimens and aged between 16 to 65 years of age (mean 34 years). Nelarabine at a dose of 1500 mg/m2/day was administered intravenously over two hours on days 1, 3 and 5 of a 21 day cycle. Five of the 28 patients (18 %) [95 % CI: 6 %—37 %] treated with nelarabine achieved a complete response (bone marrow blast counts ≤ 5 %, no other evidence of disease, and full recovery of peripheral blood counts). A total of 6 patients (21 %) [95 % CI: 8 %–41 %] achieved a complete response with or without haematological recovery. Time to complete response in both classifications of response ranged from 2.9 to 11.7 weeks. Duration of response (in both classifications of response (n=5) ranged between 15 and 195+ weeks. Median overall survival was 20.6 weeks [95 % CI: 10.4–36.4]. Survival at one year was 29% [95 % CI: 12 %–45 %].
Paediatric studies
In an open-label, multicenter study carried out by Childrens Oncology Group, nelarabine was administered intravenously over 1 hour for 5 days to 151 patients ≤ 21 years of age, 149 of whom had relapsed or refractory T-cell acute lymphoblastic leukaemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL). Eighty-four (84) patients, 39 of whom had received two or more prior induction regimens and 31 whom had received one prior induction regimen, were treated with 650 mg/m2/day of nelarabine administered intravenously over 1 hour daily for 5 consecutive days repeated every 21 days.
Of the 39 patients who had received two or more prior induction regimens, 5 (13 %) [95 % CI: 4 %–27 %] achieved a complete response (bone marrow blast counts ≤ 5 %, no other evidence of disease, and full recovery of peripheral blood counts) and 9 (23 %) [95 % CI: 11 %–39 %] achieved complete responses with or without full haematological recovery. Duration of response in both classifications of response ranged between 4.7 and 36.4 weeks and median overall survival was 13.1 weeks [95 % CI: 8.7–17.4] and survival at one year was 14 % [95 % CI: 3 %–26 %].
Thirteen (42 %) of the 31 patients treated with one prior induction regimen achieved a complete response overall. Nine of these 31 patients failed to respond to prior induction (refractory patients). Four (44 %) of the nine refractory patients experienced a complete response to nelarabine.
This medicinal product has been authorised under “exceptional circumstances”. This means that due to the rarity of the disease it has not been possible to obtain complete information on this medicinal product.
The European Medicines Agency will review any new information which may become available every year and this SmPC will be updated as necessary.
5.2 Pharmacokinetic properties
Nelarabine is a pro-drug of the deoxyguanosine analogue ara-G. Nelarabine is rapidly demethylated by adenosine deaminase (ADA) to ara-G and then phosphorylated intracellularly by deoxyguanosine kinase and deoxycytidine kinase to its 5'-monophosphate metabolite. The monophosphate metabolite is subsequently converted to the active 5'-triphosphate from, ara-GTP. Accumulation of ara-GTP in leukaemic blasts allows for preferential incorporation of ara-GTP into deoxyribonucleic acid (DNA) leading to inhibition of DNA synthesis. This results in cell death. Other mechanisms may contribute to the cytotoxic effects of nelarabine. In vitro, T-cells are more sensitive than B-cells to the cytotoxic effects of nelarabine.
In a cross-study analysis using data from four Phase I studies, the pharmacokinetics of nelarabine and ara-G were characterized in patients aged less than 18 years and adult patients with refractory leukaemia or lymphoma.
Absorption
Adults
Plasma ara-G Cmax values generally occurred at the end of the nelarabine infusion and were generally higher than nelarabine Cmax values, suggesting rapid and extensive conversion of nelarabine to ara-G. After infusion of 1,500 mg/m2 nelarabine over two hours in adult patients, mean (%CV) plasma nelarabine Cmax and AUCinf values were 13.9 µM (81 %) and 13.5 µM.h (56 %) respectively. Mean plasma ara-G Cmax and AUCinf values were 115 µM (16 %) and 571 µM.h (30 %), respectively.
Intracellular Cmax for ara-GTP appeared within 3 to 25 hours on day 1. Mean (%CV) intracellular ara-GTP Cmax and AUC values were 95.6 µM (139 %) and 2214 µM.h (263 %) at this dose.
Paediatric patients
After infusion of 400 or 650 mg/m2 nelarabine over one hour in 6 paediatric patients, mean (%CV) plasma nelarabine Cmax and AUCinf values, adjusted to a 650 mg/m2 dose, were 45.0 µM (40 %) and 38.0 µM.h (39 %), respectively. Mean plasma ara-G Cmax and AUCinf values were 60.1 µM (17 %) and 212 µM.h (18 %), respectively.
Distribution
Nelarabine and ara-G are extensively distributed throughout the body based on combined Phase I pharmacokinetic data at nelarabine doses of 104 to 2,900 mg/m2. Specifically, for nelarabine, mean (%CV) VSS values were 115 l/m2 (159 %) and 89.4 l/m2 (278 %) in adult and paediatric patients, respectively. For ara-G, mean VSS/F values were 44.8 l/m2 (32 %) and 32.1 l/m2 (25 %) in adult and paediatric patients, respectively.
Nelarabine and ara-G are not substantially bound to human plasma proteins (less than 25 %) in vitro, and binding is independent of nelarabine or ara-G concentrations up to 600 µM.
No accumulation of nelarabine or ara-G was observed in plasma after nelarabine administration on either a daily or a day 1, 3, 5 schedule.
Intracellular ara-GTP concentrations in leukaemic blasts were quantifiable for a prolonged period after nelarabine administration. Intracellular ara-GTP accumulated with repeated administration of nelarabine. On the day 1, 3, and 5 schedule, Cmax and AUC(0-t) values on day 3 were approximately 50 % and 30 %, respectively, greater than Cmax and AUC(0-t) values on day 1.
Biotransformation
The principal route of metabolism for nelarabine is O-demethylation by adenosine deaminase to form ara-G, which undergoes hydrolysis to form guanine. In addition, some nelarabine is hydrolysed to form methylguanine, which is O-demethylated to form guanine. Guanine is N-deaminated to form xanthine, which is further oxidized to yield uric acid.
Elimination
Nelarabine and ara-G are rapidly eliminated from plasma with a half-life of approximately 30 minutes and 3 hours, respectively. These findings were demonstrated in patients with refractory leukaemia or lymphoma given a dose of 1,500 mg/m2 nelarabine (adults) or a 650 mg/m2 (paediatrics).
Combined Phase 1 pharmacokinetic data at nelarabine doses of 104 to 2,900 mg/m2 indicate that mean (%CV) clearance (Cl) values for nelarabine are 138 l/h/m2 (104 %) and 125 l/h/m2 (214 %) in adult and paediatric patients, respectively, on day 1 (n = 65 adults, n = 21 paediatric patients). The apparent clearance of ara-G (Cl/F) is comparable between the two groups [9.5 l/h/m2 (35 %) in adult patients and 10.8 l/h/m2 (36 %) in paediatric patients] on day 1.
Nelarabine and ara-G are partially eliminated by the kidneys. In 28 adult patients, 24 hours after nelarabine infusion on day 1, mean urinary excretion of nelarabine and ara-G was 5.3 % and 23.2 % of the administered dose, respectively. Renal clearance averaged 9.0 l/h/m2 (151 %) for nelarabine and 2.6 l/h/m2 (83%) for ara-G in 21 adult patients.
Because the timecourse of intracellular ara-GTP was prolonged, its elimination half-life could not be accurately estimated.
Paediatric population
Limited clinical pharmacology data are available for patients below the age of 4 years.
Combined Phase 1 pharmacokinetic data at nelarabine doses of 104 to 2,900 mg/m2 indicate that the clearance (Cl) and Vss values for nelarabine and ara-G are comparable between the two groups. Further data with respect to nelarabine and ara-G pharmacokinetics in the paediatric population are provided in other subsections.
Gender
Gender has no effect on nelarabine or ara-G plasma pharmacokinetics. Intracellular ara-GTP Cmax and AUC(0–t) values at the same dose level were 2– to 3– fold greater on average in adult female than in adult male patients.
Race
The effect of race on nelarabine and ara-G pharmacokinetics has not been specifically studied. In a pharmacokinetic/pharmacodynamic cross study analysis, race had no apparent effect on nelarabine, ara-G, or intracellular ara-GTP pharmacokinetics.
Renal Impairment
The pharmacokinetics of nelarabine and ara-G have not been specifically studied in renally impaired or haemodialysed patients. Nelarabine is excreted by the kidney to a small extent (5 to 10 % of the administered dose). Ara-G is excreted by the kidney to a greater extent (20 to 30 % of the administered nelarabine dose). Adults and children in clinical studies were categorized into the three groups according to renal impairment: normal with Clcr greater than 80 ml/min (n = 56), mild with Clcr equalling 50 to 80 ml/min (n = 12), and moderate with Clcr less than 50 ml/min (n = 2). The mean apparent clearance (Cl/F) of ara-G was about 7 % lower in patients with mild renal impairment than in patients with normal renal function (see section 4.2). No data are available to provide a dose advice for patients with Clcr less than 50 ml/min.
Elderly
Age has no effect on the pharmacokinetics of nelarabine or ara-G. Decreased renal function, which is more common in the elderly, may reduce ara-G clearance (see section 4.2).
5.3 Preclinical safety data
Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows: nelarabine caused histopathological changes to the central nervous system (white matter) vacuolation and degenerative changes in cerebrum, cerebellum and spinal cord of monkeys after treatment with nelarabine daily during 23 days, at exposures below the human therapeutic exposure. Nelarabine showed in vitro cytotoxicity to monocytes and macrophages.
Carcinogenicity
Carcinogenicity testing of nelarabine has not been performed.
Mutagenicity
Nelarabine was mutagenic to L5178Y/TK mouse lymphoma cells with and without metabolic activation.
Reproduction toxicity
Compared to controls, nelarabine caused increased incidences of foetal malformations, anomalies, and variations in rabbits when given at doses approximately 24 % of the adult human dose on a mg/m2 basis during the period of organogenesis. Cleft palate was seen in rabbits given a dose approximately 2-fold the adult human dose, absent pollices in rabbits given a dose approximately 79 % of the adult human dose while absent gall bladder, accessory lung lobes, fused or extra sternebrae and delayed ossification was seen at all doses. Maternal body weight gain and foetal body weights were reduced in rabbits given a dose approximately 2-fold the adult human dose.
Fertility
No studies have been conducted in animals to assess the effects of nelarabine on fertility. However, no undesirable effects were seen in the testes or ovaries of monkeys given nelarabine intravenously at doses up to approximately 32 % of the adult human dose on a mg/m2 basis for 30 consecutive days.
6. Pharmaceutical particulars
6.1 List of excipients
Sodium chloride
Water for injections
Hydrochloric acid (to adjust the pH)
Sodium hydroxide (to adjust the pH)
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
3 years.
Atriance is stable for up to 8 hours at up to 30°C once the vial is opened.
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.
6.5 Nature and contents of container
Clear glass (Type I) vials with a bromobutyl rubber stopper, sealed with an aluminium cap.
Each vial contains 50 ml. Atriance is supplied in packs of 6 vials.
6.6 Special precautions for disposal and other handling
The normal procedures for proper handling and disposal of anti-tumour medicinal products should be adopted, namely:
— Staff should be trained in how to handle and transfer the medicinal product.
— Pregnant staff should be excluded from working with this medicinal product.
— Personnel handling this medicinal product during handling/transfer should wear protective clothing including mask, goggles and gloves.
— All items for administration or cleaning, including gloves, should be placed in high-risk, waste disposal bags for high-temperature incineration. Any liquid waste from the preparation of the nelarabine solution for infusion may be flushed with large amounts of water.
— Accidental contact with the skin or eyes should be treated immediately with copious amounts of water.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7. Marketing authorisation holder
Novartis Europharm Limited
Frimley Business Park
Camberley GU16 7SR
United Kingdom
8. Marketing authorisation number(s)
EU/1/07/403/001
9. Date of first authorisation/renewal of the authorisation
Date of first authorisation: 22 August 2007
Date of latest renewal: 18 June 2012
10. Date of revision of the text
24 April 2015
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu

责任编辑:admin


相关文章
奈拉滨注射剂(nelarabine Injection 商品名:ARRANON/Atriance)
奈拉滨注射剂Arranon(Nekarabine)
奈拉滨(nelarabine)—治疗急性成淋巴细胞性白血病 T细胞淋巴瘤新药
白血病化疗新药Arranon(nelarabine)获FDA加快批准
FDA预计年内批准葛兰素史克的抗白血病新药“奈拉滨”
奈拉滨注射液(nelarabine,Arranon)抑制DNA合成→有效抗癌
 

最新文章

更多

· Atriance(nelarabine s...
· Zydelig(idelalisib fi...
· 阿仑单抗注射剂|MabCamp...
· ERWINASE(Erwinia L-asp...
· BLINCYTO(blinatumomab)...
· MabCampath(Alemtuzuma...
· Zydelig(Idelalisib fil...
· Tasigna Capsules(Nilo...
· Bosulif tablets(BOSUTI...
· 巯嘌呤混悬剂|Purixan(M...

推荐文章

更多

· Atriance(nelarabine s...
· Zydelig(idelalisib fi...
· 阿仑单抗注射剂|MabCamp...
· ERWINASE(Erwinia L-asp...
· BLINCYTO(blinatumomab)...
· MabCampath(Alemtuzuma...
· Zydelig(Idelalisib fil...
· Tasigna Capsules(Nilo...
· Bosulif tablets(BOSUTI...
· 巯嘌呤混悬剂|Purixan(M...

热点文章

更多

· Zydelig(idelalisib fi...
· Atriance(nelarabine s...